放疗联合 GnRH 类似物高剂量比卡鲁胺：一项病例对照研究。

Radiotherapy Plus GnRH Analogue High Dose Bicalutamide: A Case Control Study.

机构信息

Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Radiotherapy Unit, Giovanni Paolo II Foundation, Catholic University of Sacred Heart, Campobasso, Italy.

出版信息

Anticancer Res. 2019 Nov;39(11):6373-6378. doi: 10.21873/anticanres.13850.

DOI:10.21873/anticanres.13850

PMID:31704870

Abstract

BACKGROUND/AIM: Radiotherapy (RT) with adjuvant hormone therapy (HT) improves prognosis in prostate cancer (PC) patients. Gonadotrophin-releasing hormone agonist (GnRHa) with luteinizing hormone-releasing hormone (LH-RH) analogues is the standard HT. High-dose antiandrogen therapy also improves survival in patients with locally advanced PC. The aim of this study was to compare the results of patients treated with RT plus GnRHa and patients treated with RT plus bicalutamide.

PATIENTS AND METHODS

Our institutional PC database was used to identify patients treated with definitive or postoperative RT +/- HT which were included in this study.

RESULTS

Three hundred and eighteen patients were retrospectively reviewed (median follow-up=56 months). Five-year biochemical relapse-free survival was 85.5% and 88.3% in patients treated with GnRHa and bicalutamide, respectively (p=0.712).

CONCLUSION

Bicalutamide may be offered as an adjuvant treatment to RT in patients who refuse GnRHa because of related side effects. Furthermore, our study justifies randomized trials comparing RT plus GnRHa and RT plus bicalutamide.

摘要

背景/目的：放疗 (RT) 联合辅助激素治疗 (HT) 可改善前列腺癌 (PC) 患者的预后。促性腺激素释放激素激动剂 (GnRHa) 联合黄体生成素释放激素 (LH-RH) 类似物是标准的 HT。高剂量抗雄激素治疗也可改善局部晚期 PC 患者的生存。本研究旨在比较接受 RT+GnRHa 治疗和 RT+bicalutamide 治疗的患者的结果。